Patent History
  • Application
    US 11/452267 2006-06-14
  • Granted
    US 20060258611 2006-11-16

granted patent: Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference

TitleInhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
Granted PatentUS 20060258611
Granted Date2006-11-16
Priority Date2006-06-14 US 11/452267
2004-05-19 US 10/848737
2003-05-19 US 10/471901P
Inventors
Issue Date2006
Citation
US Patent US 20060258611. Washington, DC: US Patent and Trademark Office (USPTO), 2006 How to Cite?
AbstractThe present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
Persistent Identifierhttp://hdl.handle.net/10722/206634

 

DC FieldValueLanguage
dc.date.accessioned2014-11-21T08:12:24Z-
dc.date.available2014-11-21T08:12:24Z-
dc.date.issued2006en_US
dc.identifier.citationUS Patent US 20060258611. Washington, DC: US Patent and Trademark Office (USPTO), 2006en_US
dc.identifier.urihttp://hdl.handle.net/10722/206634-
dc.description.abstractThe present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.en_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License for public patent documentsen_US
dc.titleInhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interferenceen_US
dc.typePatenten_US
dc.identifier.authorityZHENG, BO-JIAN=rp00353en_US
dc.identifier.authorityGUAN, YI=rp00397en_US
dc.identifier.authorityLIN, MARIE C=rp00746en_US
dc.description.naturepublished_or_final_versionen_US
dc.contributor.inventorKUNG, HSIANG-FUen_US
dc.contributor.inventorHE, MING-LIANGen_US
dc.contributor.inventorZHENG, BO-JIANen_US
dc.contributor.inventorGUAN, YIen_US
dc.contributor.inventorLIN, MARIE Cen_US
dc.contributor.inventorPENG, YINGen_US
patents.identifier.applicationUS 11/452267en_US
patents.identifier.grantedUS 20060258611en_US
patents.description.assigneeUNIV HONG KONGen_US
patents.description.countryUnited States of Americaen_US
patents.date.granted2006-11-16en_US
patents.identifier.hkutechidIMB-2003-00130-2en_US
patents.date.application2006-06-14en_US
patents.date.priority2006-06-14 US 11/452267en_US
patents.date.priority2004-05-19 US 10/848737en_US
patents.date.priority2003-05-19 US 10/471901Pen_US
patents.description.ccusen_US
patents.relation.familyU S7429656 (B2) 2008-09-30en_US
patents.relation.familyUS 2005004063 (A1) 2005-01-06en_US
patents.relation.familyU S7129223 (B2) 2006-10-31en_US
patents.description.kindA1en_US
patents.typePatent_granteden_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats